Novartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battle
Novartis is planning to file for remibrutinib’s expanded approval in relapsing multiple sclerosis by next year, putting it just behind Roche’s own BTK inhibitor fenebrutinib.
Novartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battle Read More »
